|Bid||75.36 x 900|
|Ask||75.37 x 800|
|Day's Range||75.22 - 76.14|
|52 Week Range||61.45 - 89.74|
|Beta (5Y Monthly)||0.39|
|PE Ratio (TTM)||17.30|
|Earnings Date||Oct 25, 2023 - Oct 30, 2023|
|Forward Dividend & Yield||3.00 (3.96%)|
|Ex-Dividend Date||Sep 14, 2023|
|1y Target Est||85.23|
Subscribe to Yahoo Finance Plus to view Fair Value for GILD
Stock valuations are at historically high levels. Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).
A cell therapy for multiple myeloma promises to be a major blockbuster for J&J and partner Legend, if they can increase manufacturing.
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.